Multiple Myeloma Patients Presenting with Renal Failure – Treatment Outcome from a Tertiary Cancer Center in Tamilnadu.
Abstract
Aim: To study the outcome of chemotherapy in multiple myeloma presenting with renal failure
Materials and methods: Retrospective analysis of 9multiple myeloma patients presenting with renal failure i.e serum creatinine of >1.5mg/dl (between January2013-Febrary2015) was done with respect to treatment and outcome. Induction chemotherapy with Bortezomib, Dexamethasone and Thalidomide (BDT) was given.
Results: Induction chemotherapy with BDT regimen resulted in 22 %( 2) Complete Remission (CR) and 11% (1) very good partial response(VGPR), 33.3% (3)partial remission(PR) and 33.3% (3) stable disease. Overall Survival (OS) was 42.85% at 12 months and 28.5% at 24 months. Median survival was 12months.
Conclusion: Patients who had good response to chemotherapy had reversal of renal failure and Survival in these patients (12 months) is good compared to patients who had not attained reversal of renal failure (8 months).
Full Text:
PDFReferences
Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma Pathogenesis and progntic implications. Arch InternMed 1990; 150: 1693–1695.
Blade J, Fernandez-Llama P, Bch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagned multiple myeloma. Mayo ClinProc 2003; 78: 21–33.
Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A,
Anagntopoul A et al. Renal failure in multiple myeloma: incidence,
correlations, and progntic significance. Leuk Lymphoma 2007;
: 337–341.
Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma:
reversibility and impact on the prognis. Nordic Myeloma Study
Group. Eur J Haematol 2000; 65: 175–181.
Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C
et al. Patients with multiple myeloma requiring long-term dialysis:
presenting features, response to therapy, and outcome in a series of 20
cases. Br J Haematol 1995; 91: 854–859.
Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol2001; 158: 1859–1866.
Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronalproteinaceous cast formation by low
molecular weight proteins. J Clin Invest 1990; 85: 570–576.
Pirani CL, Valeri A, D’Agati V, Appel GB. Renal toxicity of nonsteroidal anti-inflammatory drugs. ContribNephrol1987; 55:
– 175
Blade J, Rinol L. Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res ClinHaematol 2005; 18: 635–652.
Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J.
Perspectives in multiple myeloma: survival, progntic factors and
disease complications in a single centre between 1975 and 1988. QJ
Med 1991; 79: 517–525.
Abbott KC, Agodoa LY. Multiple myeloma and light chain associated
nephropathy at end-stage renal disease in the United States: patient
characteristics and survival. ClinNephrol 2001; 56: 207–210.
Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et
al. Early mortality after diagnis of multiple myeloma: analysis of patients
entered onto the United
Eriksson T, Hoglund P, Turesson I, Waage A, Don BR, Vu J et al.
Pharmacokinetics of thalidomide in patients with impaired renal function
and function and while on and off dialysis. J Pharm Pharmacol 2003;
: 1701–1706.
Ti P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S et al.
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004; 73: 98–103.
Kastritis E, Anagntopoul A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagned multiple myeloma patients treated with high de dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546–549.
Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003; 122: 160–161.
Montagut C, Bch F, Villela L, Rinol L, Blade J. Aminoglycide- associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymphoma 2004; 45:1711–1712.
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560.
Rinol L, Oriol A, Mate MV, Sureda A, Garcia-Sanchez P, Gutierrez N et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J ClinOncol 2007; 25: 4452–4458.
Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagned multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498–1505.
International myeloma working group uniform response criteria for multiple myeloma by IMWG on april 21,2010.
Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acuterenal failure by bortezomib-based chemotherapy in patients withmultiple myeloma. Haematologica 2007; 92: 1411–1414.
Kumar. Lalith Multiple Myeloma- The indian perspective: current situation, comy-2016.cme congresses.com
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University